DMAC - הכנסה תפעולית לפני ניכוי פחת diamedica.com

The prospects for DiaMedica Therapeutics (DMAC) depend on the outcomes of DM199 stroke trials and FDA approval. The company's estimated EBITDA reflects current cash dynamics, where 0.00 expresses the latest level of the metric. Simultaneously, the business is implementing eco-filtration in its laboratories. Meanwhile, a conservative R&D budget offsets potential funding shortages and delays in recruiting volunteers for Phase III.

This indicator measures cash flow from operating activities before deducting financial expenses and depreciation, allowing for the determination of the business's actual ability to generate internal resources. An analysis of absolute EBITDA confirms the development stage of DiaMedica Therapeutics (DMAC): the absence of an operating surplus reflects the cost-intensive period of clinical trials and the company's dependence on external capital.